Clinical Trial

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Study acronym: DUPLEX-AD

Terminated Phase 2

View on ClinicalTrials.gov →

Why the trial stopped

Terminated: futility criteria met at interim efficacy analysis.

Summary

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

Protocol Amendment History 2 changes

critical Trial terminated 2026-06-05

critical Reason stopped changed: — → Terminated: futility criteria met at interim efficacy analysis. 2026-06-05

Trial Details

NCT Number	NCT06881251
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Dermatitis, Atopic
Enrollment	256 participants
Start Date	2025-02-26
Primary Completion	2026-03-26 (estimated)
Study Completion	2026-04-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-31